Abcuro raised $66 million to restart development of a biologics program targeting inclusion body myositis, a rare inflammatory disorder with no approved drugs, the company said. The funding is intended to support a new study designed to support a potential biologics license application. Abcuro previously ran a Phase 2/3 study earlier this year that did not meet its primary goals, but the company pointed to positive trends among patients with less severe disease as justification for renewed trials. The cash adds runway for a disease area where patient numbers are small and endpoints are hard to validate, a dynamic that often forces sponsors to refine inclusion criteria, biomarkers, and statistical targets between attempts.